Notice of NHLBI Participation in PA-17-286 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp)"

Notice Number: NOT-HL-17-517

Key Dates
Release Date:   May 24, 2017

Related Announcements
PA-17-286

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-17-286 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp)."

The following sections of PA-17-286 have been updated to reflect participation of NHLBI participation in this Funding Opportunity Announcement.

Part 1. Overview Information

 
Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
National Heart, Lung, and Blood Institute (NHLBI)

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Kurt Marek, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7943
Email: kurt.marek@nih.gov

Grants Management Contact(s)
Ann Marie Brasile Mejac
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0164
Email: brasilea@nhlbi.nih.gov

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:


Kurt Marek, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7943
Email: kurt.marek@nih.gov